Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

Hans Hammers, MD, PhD
Published: Thursday, Nov 30, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma (RCC).

Interfering in the IDO pathway can result in a tumor microenvironment that allows for a more enhanced immune response, says Hammers.

Early data out of ASCO 2017 showed an improved response rate with the combination of an IDO inhibitor and a PD-1 inhibitor, resulting in a phase III trial comparing that combination to sunitinib (Sutent) in RCC.
 


Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma (RCC).

Interfering in the IDO pathway can result in a tumor microenvironment that allows for a more enhanced immune response, says Hammers.

Early data out of ASCO 2017 showed an improved response rate with the combination of an IDO inhibitor and a PD-1 inhibitor, resulting in a phase III trial comparing that combination to sunitinib (Sutent) in RCC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x